Atara Biotherapeutics, Inc. (NASDAQ:ATRA)‘s stock had its “buy” rating reiterated by investment analysts at Jefferies Group LLC in a research note issued to investors on Thursday. They presently have a $30.00 target price on the biotechnology company’s stock. Jefferies Group LLC’s price target points to a potential upside of 96.72% from the stock’s current price.

Other analysts also recently issued research reports about the company. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Monday, August 7th. Zacks Investment Research downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. BidaskClub downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Finally, ValuEngine downgraded Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $23.60.

Shares of Atara Biotherapeutics (NASDAQ ATRA) opened at 15.25 on Thursday. The stock’s 50 day moving average is $14.88 and its 200-day moving average is $15.88. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $23.00. The stock’s market capitalization is $466.02 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.05. On average, equities research analysts expect that Atara Biotherapeutics will post ($3.89) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (ATRA) Rating Reiterated by Jefferies Group LLC” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/atara-biotherapeutics-inc-atra-rating-reiterated-by-jefferies-group-llc/1537268.html.

In other news, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $12.65, for a total value of $75,900.00. Following the transaction, the executive vice president now owns 368,080 shares in the company, valued at approximately $4,656,212. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 5,500 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $16.49, for a total value of $90,695.00. Following the completion of the transaction, the chief executive officer now owns 731,859 shares in the company, valued at approximately $12,068,354.91. The disclosure for this sale can be found here. Insiders sold a total of 46,109 shares of company stock worth $673,304 in the last quarter. 16.10% of the stock is owned by corporate insiders.

Several institutional investors have recently modified their holdings of ATRA. Eagle Asset Management Inc. increased its position in shares of Atara Biotherapeutics by 17.8% in the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after buying an additional 225,367 shares in the last quarter. EcoR1 Capital LLC increased its position in shares of Atara Biotherapeutics by 101.5% in the first quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock worth $8,935,000 after buying an additional 219,000 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 173,184 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Atara Biotherapeutics by 15.7% in the second quarter. Neuberger Berman Group LLC now owns 967,980 shares of the biotechnology company’s stock worth $13,552,000 after buying an additional 131,465 shares in the last quarter. Finally, Camber Capital Management LLC acquired a new position in shares of Atara Biotherapeutics during the first quarter worth $2,569,000. Institutional investors own 82.95% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.